Jazz Pharmaceuticals plc (FRA:J7Z)

Jazz Pharmaceuticals Statistics

Total Valuation

FRA:J7Z has a market cap or net worth of EUR 9.25 billion. The enterprise value is 12.17 billion.

Market Cap	9.25B
Enterprise Value	12.17B

Important Dates

The next estimated earnings date is Thursday, February 26, 2026.

Earnings Date	Feb 26, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	60.77M
Shares Outstanding	n/a
Shares Change (YoY)	-10.58%
Shares Change (QoQ)	+0.67%
Owned by Insiders (%)	3.04%
Owned by Institutions (%)	99.68%
Float	58.86M

Valuation Ratios

PE Ratio	n/a
Forward PE	8.04
PS Ratio	2.61
PB Ratio	2.74
P/TBV Ratio	n/a
P/FCF Ratio	8.12
P/OCF Ratio	7.80
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 8.60, with an EV/FCF ratio of 10.68.

EV / Earnings	-38.75
EV / Sales	3.39
EV / EBITDA	8.60
EV / EBIT	15.31
EV / FCF	10.68

Financial Position

The company has a current ratio of 1.65, with a Debt / Equity ratio of 1.37.

Current Ratio	1.65
Quick Ratio	1.24
Debt / Equity	1.37
Debt / EBITDA	3.31
Debt / FCF	4.06
Interest Coverage	3.10

Financial Efficiency

Return on equity (ROE) is -9.06% and return on invested capital (ROIC) is 5.83%.

Return on Equity (ROE)	-9.06%
Return on Assets (ROA)	4.88%
Return on Invested Capital (ROIC)	5.83%
Return on Capital Employed (ROCE)	10.16%
Revenue Per Employee	1.27M
Profits Per Employee	-112,164
Employee Count	2,800
Asset Turnover	0.35
Inventory Turnover	0.65

Taxes

Income Tax	-285.79M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +31.81% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+31.81%
50-Day Moving Average	124.53
200-Day Moving Average	109.18
Relative Strength Index (RSI)	69.36
Average Volume (20 Days)	14

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	5.10

Income Statement

In the last 12 months, FRA:J7Z had revenue of EUR 3.54 billion and -314.06 million in losses. Loss per share was -5.16.

Revenue	3.54B
Gross Profit	3.26B
Operating Income	786.24M
Pretax Income	-599.85M
Net Income	-314.06M
EBITDA	1.37B
EBIT	786.24M
Loss Per Share	-5.16

Balance Sheet

The company has 1.74 billion in cash and 4.63 billion in debt, giving a net cash position of -2.88 billion.

Cash & Cash Equivalents	1.74B
Total Debt	4.63B
Net Cash	-2.88B
Net Cash Per Share	n/a
Equity (Book Value)	3.37B
Book Value Per Share	55.55
Working Capital	1.26B

Cash Flow

In the last 12 months, operating cash flow was 1.19 billion and capital expenditures -47.14 million, giving a free cash flow of 1.14 billion.

Operating Cash Flow	1.19B
Capital Expenditures	-47.14M
Free Cash Flow	1.14B
FCF Per Share	n/a

Margins

Gross margin is 91.98%, with operating and profit margins of 22.19% and -8.86%.

Gross Margin	91.98%
Operating Margin	22.19%
Pretax Margin	-16.93%
Profit Margin	-8.86%
EBITDA Margin	38.67%
EBIT Margin	22.19%
FCF Margin	32.14%

Dividends & Yields

FRA:J7Z does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	10.58%
Shareholder Yield	10.58%
Earnings Yield	-3.39%
FCF Yield	12.31%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

FRA:J7Z has an Altman Z-Score of 1.43 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.43
Piotroski F-Score	5